Evidence map›Paper›PMID 38637558›Full record

Observational studyScientific reports2024

Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study.

Gabrielle N Gaultier, Brynn McMillan, Chad Poloni, Mandy Lo, Bing Cai, Jean J Zheng, Hannah M Baer, Hennady P Shulha, Karen Simmons, Ana Citlali Márquez and 11 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 3 countries.

Gabrielle N GaultierDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada. gabrielle.gaultier@bcchr.ca.
Brynn McMillanVaccine Evaluation Center, British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Chad PoloniDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
Mandy LoDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
Bing CaiDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
Jean J ZhengVaccine Evaluation Center, British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Hannah M BaerDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
Hennady P ShulhaDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
Karen SimmonsDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
Ana Citlali MárquezBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Sofia R BartlettBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Laura CookBritish Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Megan K LevingsBritish Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Theodore SteinerBritish Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Inna SekirovBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
James E A ZlosnikBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Muhammad MorshedBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Danuta M SkowronskiBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Mel KrajdenBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Agatha N JassemBritish Columbia Centre for Disease Control, Vancouver, BC, Canada.
Manish SadaranganiDepartment of Pediatrics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
University of British Columbia · CABC Centre for Disease Control · CABC Children's Hospital · CA

Funding

Public Health Agency of Canada, BC Immunization Committee AWD-018041Public Health Agency of Canada, through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force 2122-HQ-000218
6 · The paper itself

Abstract

To evaluate immune responses to COVID-19 vaccines in adults aged 50 years and older, spike protein (S)-specific antibody concentration, avidity, and function (via angiotensin-converting enzyme 2 (ACE2) inhibition surrogate neutralization and antibody dependent cellular phagocytosis (ADCP)), as well as S-specific T cells were quantified via activation induced marker (AIM) assay in response to two-dose series. Eighty-four adults were vaccinated with either: mRNA/mRNA (mRNA-1273 and/or BNT162b2); ChAdOx1-S/mRNA; or ChAdOx1-S/ChAdOx1-S. Anti-S IgG concentrations, ADCP scores and ACE2 inhibiting antibody concentrations were highest at one-month post-second dose and declined by four-months post-second dose for all groups. mRNA/mRNA and ChAdOx1-S/mRNA schedules had significantly higher antibody responses than ChAdOx1-S/ChAdOx1-S. CD8

Indexed as

COVID-19COVID-19 VaccinesAdultAgedAngiotensin-Converting Enzyme 2AntibodiesAntibodies, ViralBNT162 VaccineCanadaChAdOx1 nCoV-19HumansMiddle AgedProspective StudiesRNA, MessengerVaccinationAngiotensin-Converting Enzyme 2AntibodiesAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesRNA, Messenger

Identifiers

PMID38637558
PMCPMC11026432
OpenAlexW4394926021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.